# Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-1

> **NCT04456049** · PHASE2 · TERMINATED · sponsor: **Ricardo Pereira Mestre** · enrollment: 7 (actual)

## Conditions studied

- COVID-19 Infection

## Interventions

- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT04456049
- **Lead sponsor:** Ricardo Pereira Mestre
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-24
- **Primary completion:** 2021-06-09
- **Final completion:** 2021-06-09
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2022-08-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04456049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04456049, "Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-1". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04456049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*